Results 21 to 30 of about 29,746 (162)
Фармацевтичний журнал, 2023 Over the past decades, health policy makers have focused on early diagnosis to introduce targeted and innovative treatments. Early diagnosis of pulmonary arterial hypertension (PAH) is associated with improved long-term survival, so screening high-risk ...
I. S. Datsenko
doaj +1 more source
Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study [PDF]
International Journal of Health Policy and ManagementBackground The global challenges posed by COVID-19 vaccinations require careful consideration by decision-makers at both the global and national levels, particularly in developing countries.
Hamidreza Jamaati +28 more
doaj +1 more source
Calculating QALYs, comparing QALY and DALY calculations [PDF]
Health Policy and Planning, 2006 Quality-adjusted life years (QALYs) have been used in the assessment of health interventions for three decades. The popularity of the QALY approach has been constantly increasing, although the debate on its theoretical underpinnings and practical implications is still ongoing.
openaire +2 more sources
International experience in determining the cost-effectiveness thresholds
Фармакоэкономика, 2019 The article reviews international methodological guidelines, regulatory documents and existing approaches to the determination of the costeffectiveness threshold (CeT), also known as the willingness-to-pay threshold (WTP), the threshold value of the ...
T. P. Bezdenezhnykh +5 more
doaj +1 more source
THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES
Фармакоэкономика, 2017 This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia, a standardized methodology to calculate QALY is in use; such an approach makes it possible to apply this universal criterion of effectiveness to the ...
N. Z. Musina, V. K. Fedyaeva
doaj +1 more source
PLoS ONE, 2022 Background Decision-making in healthcare policy involves assessing both costs and benefits. In determining the cost-effectiveness (CE) threshold, willingness to pay (WTP) per quality-adjusted life year (QALY), GDP per capita, and other factors are ...
Haru Iino +2 more
doaj +2 more sources
Measurement, modeling and QALYs [PDF]
F1000Research, 2020 Over the past 30 years, a mainstay of health technology assessment has been the creation of modeled incremental cost-per-quality adjusted life year (QALY) claims. These are intended to inform resource allocation decisions. Unfortunately, the reliance on the construction of QALYs from generic utility scales is misplaced.
Paul C. Langley, Stephen P. McKenna
openaire +2 more sources
Journal of Pain Research, 2020 Thomas G Poder,1– 3 Nathalie Carrier3 1School of Public Health, Department of Management, Evaluation and Health Policy, University of Montreal, Montreal, QC, Canada; 2Centre de recherche de l’Institut universitaire en santé mentale de ...
Poder TG, Carrier N
doaj
Human Vaccines & Immunotherapeutics, 2020 Objective To evaluate the cost-effectiveness of the current strategy combining universal vaccination with hepatitis B immunoglobulin (HBIG) treatment for infants of hepatitis B surface antigen (HBsAg) positive mothers compared with universal vaccination ...
Yanbing Zeng +6 more
doaj +1 more source
Фармакоэкономика, 2015 Utility assessment is one of the most important stages of pharmacoeconomic analysis. Most of utility researches are conducted using standard gamble method which is considered the classic instrument of health state utilities assessment.
R. I. Yagudina +2 more
doaj